Document is current
Any future updates will be listed below
-
Authors
Aubrey, Brandon J.
Cutler, Jevon A.
Bourgeois, Wallace
Donovan, Katherine A.
Gu, Shengqing
Hatton, Charlie http://orcid.org/0000-0001-9903-4291
Perlee, Sarah
Perner, Florian
Rahnamoun, Homa http://orcid.org/0000-0002-0555-2328
Theall, Alexandra C. P.
Henrich, Jill A.
Zhu, Qian http://orcid.org/0000-0001-7062-8221
Nowak, Radosław P. http://orcid.org/0000-0002-0605-0071
Kim, Young Joon
Parvin, Salma http://orcid.org/0000-0001-6111-1212
Cremer, Anjali
Olsen, Sarah Naomi http://orcid.org/0000-0002-9136-0778
Eleuteri, Nicholas A.
Pikman, Yana http://orcid.org/0000-0002-5336-0216
McGeehan, Gerard M.
Stegmaier, Kimberly http://orcid.org/0000-0003-0218-7895
Letai, Anthony http://orcid.org/0000-0002-1993-9013
Fischer, Eric S. http://orcid.org/0000-0001-7337-6306
Liu, X. Shirley http://orcid.org/0000-0003-4736-7339
Armstrong, Scott A. http://orcid.org/0000-0002-9099-4728
-
Funding
Funding for this research was provided by:
Foundation for the National Institutes of Health (CA176745, CA206963, CA204639, F32CA250240-02, 5T32HL007574-38, CA231637, CA066996)
NIH
Leukemia and Lymphoma Society (CDP)
Sara Elizabeth O’Brien Trust
Damon Runyon Cancer Research Foundation (DRSG: 26-18, DRR-50-18)
Breast Cancer Research Foundation (BCRF-20-100)
- License Information
-
More Information
Article History
Received: 15 April 2021
Accepted: 11 March 2022
First Online: 9 May 2022
Competing interests
: S.A.A. has been a consultant and/or shareholder for Neomorph, Imago BioSciences, Vitae–Allergan Pharma, Cyteir Therapeutics, C4 Therapeutics, Accent Therapeutics and Mana Therapeutics. S.A.A. is an inventor on a patent application related to MENIN inhibition WO/2017/132398A1. S.A.A. has received research support from Janssen, Novartis, Syndax and AstraZeneca. X.S.L. is a cofounder, board member, SAB and consultant of GV20 Oncotherapy and its subsidiaries; an SAB of 3DMedCare; a consultant for Genentech; and a stockholder of Abbott Laboratories, Amgen Inc, Johnson & Johnson, Merck & Co, Inc. and Pfizer, Inc.; and receives sponsored research funding from Takeda and Sanofi. G.M.M. is a shareholder of Syndax Pharmaceuticals. B.J.A. is a former employee of the Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, and receives proceeds from royalties and milestone payments related to the BCL2 inhibitor ABT-199 (venetoclax). E.S.F. is an equity holder and scientific advisor for Civetta Therapeutics, Jengu Therapeutics (board of directors) and Neomorph; a shareholder in C4 Therapeutics; and a consultant to EcoR1 Capital, Sanofi, Astellas, Deerfield and RA Capital. The Fischer laboratory receives or has received research funding from Novartis, Astellas, Deerfield and Ajax. All other authors declare no potential conflicts of interest.
